SCHEMBL29523919

SCHEMBL29523919

COC(=O)[C@@H]1C[C@@H](Oc2cccc(C)c2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.47
NR1H3 Q13133 1/20 0.47
P2RX3 P56373 1/20 0.46
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
MCL1 Q07820 7/20 0.43
HRH3 Q9Y5N1 2/20 0.42
KCNH2 Q12809 1/20 0.42
MGLL Q99685 1/20 0.41
PTPN1 P18031 1/20 0.40
EPHX2 P34913 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
UCHL1 P09936 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30530834 1.00 NR1H2 (0.47) NR1H2NR1H3P2RX3CYP1A2POLB
SCHEMBL3862645 0.90 P2RX3 (0.47) NR1H2NR1H3P2RX3CYP1A2POLB
SCHEMBL31336371 0.88 P2RX3 (0.46) NR1H2NR1H3P2RX3CYP1A2POLB
SCHEMBL13481692 0.88 P2RX3 (0.51) NR1H2NR1H3P2RX3MCL1HRH3
SCHEMBL26940527 0.88 P2RX3 (0.46) NR1H2NR1H3P2RX3CYP1A2POLB
SCHEMBL24739408 0.88 HRH3 (0.54) NR1H2NR1H3P2RX3MCL1HRH3
SCHEMBL12589826 0.88 P2RX3 (0.51) NR1H2NR1H3P2RX3MCL1HRH3
SCHEMBL13106875 0.88 P2RX3 (0.51) NR1H2NR1H3P2RX3MCL1HRH3
SCHEMBL1198567 0.88 P2RX3 (0.51) NR1H2NR1H3P2RX3MCL1HRH3
SCHEMBL26940536 0.88 P2RX3 (0.46) NR1H2NR1H3P2RX3CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
WO-2022066774-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2022-03-31 WO disclosed